Drugs / Pneumovax NP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT01403805 | Nov 2009 → Oct 2010 | pneumonia | Yubari Kibounomori | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02592486 Comparator | Nov 2015 → Mar 2016 | bacterial pneumonia, influenza | Kameda Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumovax NP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02592486 ↗ |
| Known as | PPV23 | “We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types.” NCT02592486 ↗ |
| Modality | Vaccine | “pneumococcal plus influenza vaccinations” NCT01403805 ↗ |
| Route | Subcutaneous | “Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day” NCT01403805 ↗ |